Central Pharmaceuticals (DHA:CENTRALPHL) Total Operating Expense: BDT9.52 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:CENTRALPHL Central Pharmaceuticals Ltd DHA:CENTRALPHL
66 GF Score
Price BDT12.00
GF Value BDT12.06
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Central Pharmaceuticals Total Operating Expense?

Central Pharmaceuticals DHA:CENTRALPHL +0.84% 66 Total Operating Expense is BDT9.52 Mil as of Mar. 2026. GuruFocus rates DHA:CENTRALPHL with a GF Score™ of 66/100 and a GF Value™ of BDT12.06 (Fairly Valued). The stock has 5 warning signs investors should review.

Central Pharmaceuticals's Total Operating Expense for the three months ended in Mar. 2026 was BDT2.04 Mil. Central Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was BDT9.52 Mil.

Central Pharmaceuticals Total Operating Expense Related Terms

Central Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Central Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Central Pharmaceuticals Total Operating Expense Chart

Central Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.57 15.88 10.54 13.03 7.05

Central Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 3.84 1.85 1.78 2.04
DHA:CENTRALPHL
66GF Score
Central Pharmaceuticals Ltd DHA:CENTRALPHL
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Central Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT9.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of BDT9.52 Mil mean?
Central Pharmaceuticals (DHA:CENTRALPHL) has a Total Operating Expense of BDT9.52 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Central Pharmaceuticals and its competitors.
Is Central Pharmaceuticals' Total Operating Expense too high?
Central Pharmaceuticals' current Total Operating Expense is BDT9.52 Mil. Overall, Central Pharmaceuticals has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Central Pharmaceuticals' Total Operating Expense compare to ZTS and UTHR?
Central Pharmaceuticals' Total Operating Expense of BDT9.52 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Central Pharmaceuticals and its competitors. Central Pharmaceuticals's current Total Operating Expense is BDT9.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Central Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Central Pharmaceuticals (DHA:CENTRALPHL) is currently considered Fairly Valued. The stock's GF Value™ is BDT12.06, compared to a current price of BDT12.00 — trading 0.5% below its estimated fair value. The current Total Operating Expense is BDT9.52 Mil. Central Pharmaceuticals' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Central Pharmaceuticals (DHA:CENTRALPHL), the current Total Operating Expense is BDT9.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Central Pharmaceuticals (DHA:CENTRALPHL) Overvalued in 2026?

Based on GuruFocus' analysis, Central Pharmaceuticals stock appears to be undervalued. The current stock price of BDT12.00 is trading 0.5% below its estimated GF Value™ of BDT12.06. GuruFocus considers Central Pharmaceuticals to be Fairly Valued.

Key valuation signals for DHA:CENTRALPHL:

  • Total Operating Expense: BDT9.52 Mil
  • GF Value™: BDT12.06 vs. price of BDT12.00 (0.5% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the DHA:CENTRALPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Central Pharmaceuticals Business Description

Address South West Darus Salam Road, 2-A/1, 2nd Floor, Mirpur - 1, Dhaka, BGD, 1216
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished pharmaceutical formulations, including tablets, capsules, liquids, ointments, and injectables, covering therapeutic areas such as anti-infectives, cardiovascular treatments, pain management, and gastrointestinal remedies. It conducts production and sales exclusively in the domestic market through its own facilities and distribution network. The company generates revenue from the sales of its pharmaceutical preparations.
66GF Score

Get the complete analysis for DHA:CENTRALPHL

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT12.00
Price
BDT12.06
GF Value